Be part of our community by subscribing to our newsletters! Follow the steps below.

1. Subscribe to our Announcement Newsletter. You will receive our news about what do you need to know about our work and the resources available for you. You need to confirm your subscription by email (check your email box and confirm your subscription)

2. Choose your favorite writer. We constantly look for the top minds on the pharmaceutical marketing industry. You can subscribe to their article on their pages and receive every article on your inbox. 

3. Choose the Newsletter that better fits you needs. We recommend the Editor’s pick to receive everything you need to know in one weekly email. 

4. All our newsletters needs to be confirmed by email. After you subscribe on our webpage, you will receive an email asking for your confirmation by clicking a link. Click that link if you want to receive the newsletter. If you don’t receive the email, check your spam box and add our email to your safe sender list. If you address belongs to a company, you may need to forward your confirmation email to your tech department to ask them to add our domain to your company safe sender list. 

You can start here by subscribing to our main Newsletter. Confirm your subscription by clicking CONFIRM on the email you will receive after complete the subscription form.

Don’t forget to check for our other newsletters! Check this page for several options we have for all our users!

NEWSLETTER ANNOUCEMENTS




TPMG FEATURED WRITER NEWSLETTER




- Advertisement -

Top 10 Tips to Increase Engagement During Virtual Events

If you are a member of the Medical Affairs Professional Society (MAPS), you might have caught our popular webinar on how COVID-19 has impacted (and will continue to impact) live events. As part of this webinar, we discussed how engagement can be enhanced during virtual events. I also recently...

Top 10 Tips for Running a Successful Virtual Event

The ways that pharmaceutical and scientific communities attend meetings and events completely changed in 2020. Virtual events are rapidly improving, as are the platforms that host them. Based on 13 years of experience with virtualizing meetings and events, here are my top 10 tips for running a successful virtual...

2020: looking back at the year when everything changed

A version of this article was previously published on Pharmaphorum. I think it’s fair to say that 2020 will not be particularly missed by anyone. Many started the year with big plans, whether for overseas trips, weddings, or industry events, and then the unthinkable happened. While the world first heard...

Top 10 Tips for Creating Company Culture in a...

For many companies, the transition from in-office to remote or flexible work at the beginning of the pandemic may have started off a bit rocky. However, a recent survey from LinkedIn shows that, among Canada’s newly remote workforce, the original concerns around a lack of productivity or focus appear...

Natalie Yeadon´s Newsletter




- Advertisement -

Digital technologies: Pharma’s answer to achieving net zero emissions?

A version of this article was previously published in the Journal of mHealth. As I wrote about earlier this year, it is clear that the climate crisis is no longer something for future generations to worry about, it’s already here and requires our urgent and undivided attention. The Pacific Northwest...

Health literacy in the time of COVID-19

A version of this article was previously published on Pharmaphorum. In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health literacy has never been more important. Health literacy is a complex phenomenon...

Top-10 ways that Pharma teams can fight the climate...

Two years ago, I first wrote about why Pharma should care about global warming. Since then, there have been some signs of more companies changing their practices to be more sustainable. Likewise, at Impetus Digital, we have made a commitment to become carbon-neutral by 2030 at the latest (off...

Alzheimer’s Researchers Release Free Apps to Track Memory and...

Alzheimer's Disease Researchers at California based Leucadia Therapeutics released a panel of eight apps today to help people track memory and cognition. The new apps are ProCogny Memory Tracker, Infinite Mahjong, Iconic Sudoku, Word Recall, Connectors, Image Recall, Pattern Busters, and Speed Demon. The ProCogny Memory Tracker includes a non-clinical version...

EDITOR´S PICK




- Advertisement -

Merck and Ridgeback Statement on Positive FDA Advisory Committee...

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided the following statement at the conclusion of the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) regarding the Emergency Use Authorization (EUA) application for molnupiravir...

Merck and Ridgeback Biotherapeutics Provide Update on Results from...

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the MOVe-OUT study of molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine for COVID-19. Data are now available from all enrolled participants (n=1433). In this...

QIAGEN reaffirms effectiveness of its SARS-CoV-2 PCR tests in...

HILDEN, Germany & GERMANTOWN, Maryland--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections in light of the emergence of a new variant of concern detected in South Africa. QIAGEN has successfully assessed its SARS-CoV-2...

Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19...

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq:BNTX) today announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in individuals 12 through 15 years of age. The updated findings from the companies’ pivotal Phase 3 trial show that...

LOOK WHO IS ON THE MOVE!




- Advertisement -

AbCellera Announces the Appointment of Neil Aubuchon as Chief...

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, announced today the appointment of Neil Aubuchon as Chief Commercial Officer (CCO). Mr. Aubuchon brings over 20 years of experience in strategic planning, operations, and leadership for global biopharmaceutical companies, including...

Alpha Cognition Appoints Cedric O’Gorman, M.D., MBA as Chief...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF)(“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced the appointment of Cedric O’Gorman, M.D., as the Company’s Chief Medical Officer. Dr....

Venatorx Pharmaceuticals Names Scott McConnell, Pharm.D. as Vice President,...

MALVERN, Pa.--(BUSINESS WIRE)--Venatorx Pharmaceuticals today announced that Scott McConnell, Pharm.D. has joined the Company as Vice President, Medical Affairs. With over 20 years’ experience in infectious disease, oncology, rare and orphan diseases and academia, Dr. McConnell will be responsible for leading the medical affairs function at Venatorx and will...

Dominik Belloin Joins biolog-id’s Board of Directors

PARIS--(BUSINESS WIRE)--Biolog-id, a global leader in the traceability of sensitive therapeutic products, has just co-opted Dominik BELLOIN within the company’s board. He will sit alongside Pierre Lesourd, Jean-Louis Colders, Jacques Simonnet and Jean-Claude Mongrenier. Graduated from ESSEC and Harvard Business School (MBA), Dominik Belloin began his career at Goldman Sachs...

INDUSTRY NEWS




- Advertisement -

Resilience Acquires SwiftScale Biologics, a Leader in Cell-Free Protein...

SAN DIEGO--(BUSINESS WIRE)--National Resilience, Inc. (Resilience), a technology focused manufacturing company dedicated to broadening access to complex medicines, today announced the acquisition of SwiftScale Biologics, a San Leandro, California-based company developing cell-free protein synthesis (CFPS) technology. CFPS eliminates the constraints of using living cells in the drug manufacturing process, resulting...

Omnicell to Acquire ReCept

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced it has entered into a definitive agreement with ReCept Holdings, Inc., a leading provider of specialty pharmacy management services for health systems, clinics, and physician groups,...

Takeda’s LIVTENCITY™ (maribavir) Now Available for Certain Individuals Ages...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the United States commercial availability of LIVTENCITY™ (maribavir), the first and only treatment for adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to...

Covid – 19: Laboratoire Cerba Detects First Case of...

ISSY-LES-MOULINEAUX, France--(BUSINESS WIRE)--Laboratoire Cerba, a global leader in specialized clinical pathology and member of the Cerba HealthCare Group, has detected a case of the Omicron variant from the sample of a patient arriving from Nigeria who was tested at Roissy Charles De Gaulle airport. The authorities - Santé Publique...

REGULATORY AFFAIRS




VBI Vaccines Announces FDA Approval of PreHevbrio™ for the...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the U.S. Food and Drug Administration (FDA) has approved PreHevbrio™ for the prevention of infection caused by all known subtypes of...

U.S. FDA Accepts for Priority Review the Supplemental Biologics...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental Biologics License Application (sBLA) for VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) for the prevention of invasive pneumococcal disease in children...

LYNPARZA® (olaparib) Granted Priority Review in the US for...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s supplemental New Drug Application (sNDA) for LYNPARZA® (olaparib) has been accepted and granted Priority Review in the US for the adjuvant treatment of patients with BRCA-mutated (BRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery. LYNPARZA is being...

FDA Accepts Regulatory Submission of Supplemental New Drug Application...

KENILWORTH, N.J.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that a supplemental New Drug Application (sNDA) for LYNPARZA has been accepted and granted priority review by the U.S. Food and Drug Administration (FDA) for the adjuvant treatment of patients with...
Get a free copy of "Cracking the Generics Code"

Looks like you are using an ad-blocking browser extension. We request you to whitelist our website on the ad-blocking extension and refresh your browser to view the content.